Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2018-06-21
DOI
10.2217/fon-2018-0087
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The value of biomarkers in bone metastasis
- (2017) Stella D'Oronzo et al. EUROPEAN JOURNAL OF CANCER CARE
- Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
- (2017) Hiroji Uemura et al. International Journal of Clinical Oncology
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
- (2017) Justin Guinney et al. LANCET ONCOLOGY
- Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet
- (2017) Daniel P. Petrylak et al. Targeted Oncology
- Navigating the evolving therapeutic landscape in advanced prostate cancer
- (2017) E. David Crawford et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer
- (2017) Kai H. Hammerich et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
- (2016) Phillip Mikah et al. BMC CANCER
- Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients
- (2016) Begoña Mellado et al. Clinical Genitourinary Cancer
- Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
- (2016) Fred Saad et al. LANCET ONCOLOGY
- Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
- (2016) Samanta Salvi et al. Oncotarget
- Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study
- (2016) Elena Verzoni et al. Oncotarget
- Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation
- (2016) Anthony S. Malamas et al. Oncotarget
- Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
- (2016) Shimpei Yamashita et al. BMC Urology
- CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
- (2016) Anitha B. Alex et al. Therapeutic Advances in Medical Oncology
- A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
- (2015) K. N. Chi et al. ANNALS OF ONCOLOGY
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
- (2015) Jack Schalken et al. BJU INTERNATIONAL
- Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
- (2015) Peter F. Mulders et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)
- (2015) Martin Boegemann et al. CURRENT CANCER DRUG TARGETS
- The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer
- (2015) R.J. van Soest et al. EUROPEAN JOURNAL OF CANCER
- Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer
- (2015) Karim Fizazi et al. EUROPEAN UROLOGY
- Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis
- (2015) Diane S. Abou et al. JNCI-Journal of the National Cancer Institute
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
- (2015) Michele Iuliani et al. Oncotarget
- Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis
- (2015) Diane S. Abou et al. JNCI-Journal of the National Cancer Institute
- Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy
- (2015) D. J. George et al. Cancer Immunology Research
- Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer
- (2015) Janet E. Brown et al. NEOPLASIA
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- (2014) Dana E. Rathkopf et al. EUROPEAN UROLOGY
- Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis
- (2014) Kyung Seok Han et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
- (2014) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421
- (2014) Primo N. Lara et al. JNCI-Journal of the National Cancer Institute
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- (2014) Oliver Sartor et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer121Funding/support: This research was supported and funded through the Center for Prostate Disease Research (CPDR), the Uniformed Services University of the Health Sciences, the Intramural Research Program of the Clinical Research Center, and the National Cancer Institute, National Institutes of Health, Bethesda, MD, US.2Presentations: These data were presented at the 2012 Annual Meeting of the American Urological Association in Atlanta, GA.
- (2014) Adam R. Metwalli et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Abiraterone in the treatment of metastatic castration-resistant prostate cancer
- (2014) Elahe Mostaghel Cancer Management and Research
- Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
- (2013) A. Bahl et al. ANNALS OF ONCOLOGY
- Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer
- (2013) Rhonda L. Bitting et al. CANCER JOURNAL
- Castrate-resistant prostate cancer
- (2013) Song Zhao et al. CURRENT OPINION IN UROLOGY
- Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
- (2013) John M. Fitzpatrick et al. EUROPEAN UROLOGY
- Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer
- (2013) Hideyasu Matsuyama et al. International Journal of Clinical Oncology
- Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis
- (2013) Mari I. Suominen et al. JNCI-Journal of the National Cancer Institute
- Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy
- (2013) S. Halabi et al. JNCI-Journal of the National Cancer Institute
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
- (2013) David I Quinn et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
- (2012) S. Nilsson et al. EUROPEAN JOURNAL OF CANCER
- Prostate Cancer Cells and Bone Stromal Cells Mutually Interact with Each Other through Bone Morphogenetic Protein-mediated Signals
- (2012) Hikaru Nishimori et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- (2012) Christopher J Logothetis et al. LANCET ONCOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
- (2012) Yasser Rehman et al. Drug Design Development and Therapy
- Human Prostate Cancer Harbors the Stem Cell Properties of Bone Marrow Mesenchymal Stem Cells
- (2011) H. E. Zhau et al. CLINICAL CANCER RESEARCH
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)
- (2011) Gary JR Cook et al. EJNMMI Research
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
- (2010) M.-L. Zhu et al. CANCER RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Cabazitaxel
- (2010) Matthew D. Galsky et al. NATURE REVIEWS DRUG DISCOVERY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy
- (2010) Guru Sonpavde et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
- (2009) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy
- (2009) Kenji Kuroda et al. PROSTATE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Tissue-nonspecific Alkaline Phosphatase Is Required for the Calcification of Collagen in Serum
- (2008) Paul A. Price et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More